News
By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...
Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...
Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...
Hosted on MSN1mon
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugsPeople taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.
Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results